fda-and-biotech News
Immix BioPharma Surges 15% on Upsized $100M Offering
Strong investor demand, fueled by promising cancer therapy data, allows the biotech to price its offering at a premium, sending shares to a 52-week high.
Structure Therapeutics Poised for Pivotal Oral Obesity Drug Data
Investors keenly watch Monday's release of Phase 2 results for aleniglipron, a contender in the multi-billion dollar GLP-1 market dominated by injectables.
BeiGene's Sonrotoclax Shows Near-Total Cancer Remission in Leukemia Trial
Experimental BCL2 inhibitor, in combination with Brukinsa, achieves 100% response rate and deep remission in treatment-naive CLL patients at ASH 2025.
Ipsen Pipeline Boosted by Promising AML Data from ImCheck Unit
ICT01 drug, from the recently acquired ImCheck Therapeutics, shows durable responses and improved survival signals in hard-to-treat leukemia patients.
Lyell Shares Surge on Impressive Lymphoma Drug Trial Results
Company reports 93% response rate for its Ronde-Cel therapy at the prestigious ASH annual meeting, positioning it as a strong future contender in a competitive cancer market.
Prime Medicine Surges on Landmark Gene Editing Data in NEJM
Shares climb as PM359 shows high efficacy in rare disease, yet company seeks partner for the program amid strategic shift to other therapies.
AbbVie Bolsters Oncology Franchise with Strong Epkinly Data
Pivotal Phase 3 results for its blood cancer drug, developed with Genmab, show a 79% reduction in disease progression, solidifying its recent full FDA approval.
Zai Lab Secures Key Drug Renewals on China's Reimbursement List
The strategic win provides a long-term catalyst for the biotech firm as its stock trades near a 52-week low following a recent earnings miss.